(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 19 February 2004 (19.02.2004)

PCT

(10) International Publication Number WO 2004/014373 A1

- (51) International Patent Classification7: A61K 31/436, A61P 27/02
- (21) International Application Number:

PCT/JP2003/010105

- (22) International Filing Date: 8 August 2003 (08.08.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/402,061 9 August 2002 (09.08.2002)

- (71) Applicant (for all designated States except US): SU-CAMPO PHARMACEUTICALS, INC. [US/US]; 4733 Bethesda Avenue, Suite 450, Bethesda, MD 20814 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): UENO, Ryuji [JP/US]; 11025 Stanmore Drive, Potomac, Montgomery, MD 20854 (US).
- (74) Agent: TAKASHIMA, Hajime; Fujimura Yamato Seimei Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0044 (JP).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO. SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING FK506 DERIVATIVES AND THE IR USE FOR THE TREATMENT OF ALLERGIC DISEASES

(57) Abstract: The invention provides ophthalmic compositions and methods treating the symptoms of ocular allergies. The principle active ingredient in these compositions and methods is macrolide compound, such as tacrolimus, ascomycin and rapamycin and their derivatives. Optimal concentrations and dosing regimens are provided.